Since PAI-1 is a rapid inhibitor of tissue-type plasminogen activator, the major proteolytic activator of plasminogen, high plasma PAI-1 activity is thought to be linked to increased risk of coronary thrombosis. Elevated PAI-1 expression has also been demonstrated in atherosclerotic plaques, 6, 7 suggesting that PAI-1 may play a role in atherogenesis as well. Several common polymorphisms have been discovered in the PAI-1 locus, 8 -11 some of which have been reported to be associated with plasma PAI-1 activity. In particular, the 4G allele of the 4G/5G polymorphism in the promoter region has been linked to higher PAI-1 levels in healthy individuals, 12, 13 in patients with previous myocardial infarction 10, 13 or suspected CHD, 14 and in patients with NIDDM. 15, 16 The prevalence of the 4G allele was also found to be significantly higher in patients with myocardial infarction before the age of 45 than in populationbased control subjects (allele frequencies of .63 versus .53), 12 and the 4G allele has recently been linked to an increased risk of coronary artery disease also in middle-aged subjects. 14 However, the association between the 4G/5G polymorphism and plasma PAI-1 activity has not been observed uniformly. 11, 13 Furthermore, no association between 4G/5G genotype and myocardial infarction was found in the ECTIM study, examining postinfarction patients recruited from different geographical and cultural areas. 13 Both environmental and genetic factors contribute to determining plasma PAI-1 activity. A striking feature of PAI-1 is its positive association with the VLDL triglyceride concentration. 17 There is also some indication that the potential triglyceride regulation of PAI-1 is mainly confined to individuals with a certain PAI-1 genotype. Subjects who are homozygous for the HindIII noncutting allele (genotype 1/1) of the 3Ј flanking region of the PAI-1 gene have higher plasma PAI-1 activity in the presence of a raised VLDL triglyceride concentration than individuals who are homozygous for the cutting allele (genotype 2/2), with the heterozygotes lying in between. 8 This finding suggests that the HindIII polymorphism could be in linkage disequilibrium with a base change at a site of functional importance in the regulation of PAI-1 by VLDL. Furthermore, the 4G/5G polymorphic region in the PAI-1 promoter has been implicated in an allele-specific response to triglycerides in studies of patients with NIDDM, in whom the triglyceride level and its interaction with the 4G/5G genotype appeared to be strong determinants of plasma PAI-1 activity. 15, 16 A genotype-specific association between triglyceride level and PAI-1 antigen concentration was found also in patients undergoing coronary angiography because of chest pain.
14 However, such gene/environment interaction was not encountered in healthy individuals or postinfarction patients in the ECTIM study 13 or in healthy participants of the PRIME study.
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Endothelial cell synthesis and secretion of PAI-1 is indicated to contribute to the regulation of plasma PAI-1 activity. 18 Furthermore, VLDL induces secretion of PAI-1 from cultured HUVECs. 19, 20 In the present study, we have characterized an element in the PAI-1 promoter that mediates VLDL induction of PAI-1 in endothelial cells.
The promoter element is located downstream of and adjacent to the 4G/5G polymorphic site. A VLDL-inducible transcription factor shows competitive binding, with the transcription factors binding to the 4G/5G polymorphic site. Competition between the 5G allele-specific transcriptional repressor protein and the VLDL-inducible factor could explain the 4G/5G allele-specific relation between VLDL triglyceride and PAI-1 activity levels in plasma.
Methods

DNA Constructs
For EMSA and footprinting analysis, double-stranded oligonucleotides were designed. The oligonucleotides used in EMSA are shown in Figs 2A and 5. In the methylation interference assay and the DNase I footprinting, a double-stranded oligonucleotide of the Ϫ676/Ϫ641 segment of the human PAI-1 promoter with flanking cytosine residues (CGGGGAGTCAGCCGTGTATCATCGGAGGCGGCCGGGC) was constructed. The probes were end labeled with [␥- 32 P]ATP at either end using T4 polynucleotide kinase. 21 The 2ϫ5G-HCAT and the 2ϫ4G-HCAT vectors, containing the 4G/5G polymorphic site coupled to a minimal and heterologous promoter, were constructed as described earlier.
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The 5G-PAI-pCAT and the 4G-PAI-pCAT comprise the human PAI-1 sequences Ϫ805/Ϫ804 to ϩ17. Polymerase chain reaction primers with flanking Pst I and Xba I sites were used (upstream primer: AACTGCAGGCTTTTACCATGGTAACCCC; downstream primer: GCTCTAGAGCCAAACACAGCTGTGCTC). The polymerase chain reaction products from amplifying the PAI-1 promoter from genomic DNA of individuals who were homozygous for either the 4G or 5G allele were inserted into the Pst I and Xba I sites of the pCAT-Basic vector (Promega). The correct sequence of the inserts was tested by DNA sequencing. The truncated promoter constructs Ϫ708-PAI-pCAT and Ϫ609-PAI-pCAT were constructed from the 4G-PAI-pCAT as described above with the upstream polymerase chain reaction primers AACTGCAGCAGACGGACTCCCAGAGC (Ϫ708) and AACTGCAGCCTGAATGCTCTTACACACG (Ϫ609), respectively. The 4G-DEL-PAI-pCAT plasmid was constructed using the Altered Sites II in vitro mutagenesis system (Promega). A 9-bp deletion was introduced just downstream of the 4G/5G polymorphic site of the 4G-PAI-pCAT construct (see Fig 4A) by using a mutagenic oligonucleotide (ACAGAGAGAGTCTGGACACGTGGGGAGTA TCATCGGAGGCGGCCGGGCACATGG).
VLDL Preparation and Cell Culture
VLDL for incubation with HUVECs was prepared by densitygradient ultracentrifugation. 22 The endotoxin content in the VLDL preparations was tested by using a Limulus amebocyte lysate assay (COATEST Endotoxin, Endosafe Inc). Endotoxin levels were shown to be Ͻ0.1 ng/mg protein. HUVECs were cultured as described earlier.
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Transfection Assay
HUVECs were transfected using a calcium phosphate-precipitation method as described by Descheemaeker et al. 23 pRSV-␤-Galactosidase (Promega) or luciferase control vector (Promega) was cotransfected as an internal control.
EMSA
Nuclear extracts were prepared according to Alksnis et al. 24 All buffers were freshly supplemented with 0.7 g/mL leupeptin, 16.7 g/mL aprotinin, 0.5 mmol/L PMSF, and 5 mmol/L 2-mercaptoethanol. The protein concentration in the extracts was estimated by the method of Kalb and Bernlohr. 25 Incubation for EMSA was conducted as described.
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Methylation Interference and DNase I Footprinting
Methylation interference was conducted essentially as described previously. 21 The methylated DNA fragments were analyzed on an 11% (wt/vol) denaturing polyacrylamide/bisacrylamide (19:1) gel. DNase I footprinting was conducted using the same DNA fragment, labeled at either end. Partial DNase I digestion was performed as described earlier, 26 except that the reaction was terminated with 0.02 mol/L Na 2 EDTA and directly put on ice. The different protein:DNA complexes were directly separated by EMSA as described above. Retarded DNA fragments were electroblotted onto a Schleicher & Schuell diethylaminoethyl membrane and analyzed on an 11% (wt/vol) denaturing polyacrylamide/bisacrylamide (19:1) gel.
Statistical Methods
Differences in continuous variables between two groups were tested by paired or unpaired t tests.
Results
VLDL-Induced PAI-1 Expression and the 4G/5G Polymorphic Site
Because VLDL induction of PAI-1 in endothelial cells may at least in part be mediated by transcriptional activation, transfection studies were performed in HUVECs to further examine potential 4G/5G allele-specific mechanisms by which VLDL could enhance PAI-1 expression. Fragments (804 bp) of the PAI-1 promoter that contained either the 4G or 5G allele were coupled to a CAT gene and transiently transfected into HUVECs ( Fig 1A) . As shown in Fig 1B and 1C , VLDL induced transcription of the PAI-1 promoter in HUVECs. Maximum induction was obtained at 0.075 mg VLDL per milliliter culture medium (data not shown). There was a tendency to an allele-specific response to VLDL. The promoter fragment containing the 4G allele showed a slightly higher promoter activity in response to VLDL than did the promoter fragment containing the 5G allele (3.8Ϯ1.0-fold induction, meanϮSD, nϭ4, versus 2.3Ϯ0.9-fold induction, meanϮSD, nϭ6; Pϭ.06 in an unpaired t test).
We have recently demonstrated in HUVECs that both the 4G and 5G alleles bind a transcriptional activator (factor A), whereas the 5G allele also binds a repressor protein (factor B) to an overlapping binding site. 12 The 4G/5G allele-specific
Selected Abbreviations and Acronyms
CAT ϭ chloramphenicol acetyltransferase CHD ϭ coronary heart disease EMSA ϭ electromobility shift assay 4G/5G ϭ 4/5 guanosine HUVEC ϭ human umbilical vein endothelial cell PAI-1 ϭ plasminogen activator inhibitor-1 PPAR ϭ peroxisomal proliferator activator receptor VLDLRE ϭ VLDL response element differences in the relations between the VLDL triglyceride and PAI-1 activity levels in plasma thus suggest that the transcription factors binding to this polymorphic region could be involved in an activation of the PAI-1 promoter mediated by VLDL. We therefore performed an EMSA on the 4G/5G polymorphic region, using VLDL-induced nuclear extracts from HUVECs. However, we could detect neither any increased binding of the common factor to this region nor of the 5G allele-specific factor (data not shown). Furthermore, a transfection assay using two tandem copies of a 30-bp DNA segment containing either the 4G or 5G allele sequence inserted upstream of a minimal and heterologous promoter driving the CAT gene 12 did not respond to VLDL when transiently transfected into HUVECs (data not shown). These results taken together allow the conclusion that the two proteins (factors A and B) showing sequence-specific binding to the 4G and 5G sequences are not directly involved in an activation of the PAI-1 promoter mediated by VLDL.
The fact that the VLDL induction of PAI-1 in HUVECs is mediated by transcriptional activation and seems to be influenced by the 4G/5G site may suggest that a region of the PAI-1 promoter adjacent to the 4G/5G site is involved.
Localization of the VLDLRE in the PAI-1 Promoter
To localize the VLDLRE within the PAI-1 promoter, we next constructed several truncations of the promoter region coupled to a CAT gene and transfected the new constructs into HUVECs. Successive 100-bp segments were deleted from the initial promoter construct, which contained the 804 bp located upstream of the start of transcription. The results obtained from induction of transiently transfected cells with 0.075 mg/mL VLDL are shown in Fig 1D. The VLDL response was lost in the construct containing 609 bp of the promoter region. This finding indicates that the VLDL response region is located within the 609 to 708 bp upstream of the transcription start site in the PAI-1 promoter. We therefore evaluated potential binding regions for any VLDL-induced transcription factor(s) that could mediate transcriptional activation. For this purpose, three overlapping EMSA probes, in addition to the 4G/5G probe, were constructed that covered the Ϫ717 to Ϫ607 region (Fig 2A) . HUVECs were induced with 0.075 mg/mL VLDL for 1 to 24 hours, and nuclear extracts were prepared. Neither the Ϫ717/Ϫ684, Ϫ689/Ϫ665 (4G/5G), nor Ϫ642/ Ϫ607 probe bound any VLDL-inducible factor (data not shown). However, the probe covering the Ϫ672 to Ϫ637 region of the promoter showed increased binding of one factor (Fig 2B) . The specificity of the binding was analyzed by including nonlabeled EMSA probes in excess as competitors. Fig 2C shows that the VLDL-induced factor exhibits sequence-specific binding, as the band induced by VLDL was not decreased when either the Ϫ717/Ϫ684 probe (lane 3) or the Ϫ642/Ϫ607 probe (lane 5) was added as competitor, whereas the VLDL-induced band diminished when using the same probe (Ϫ672/Ϫ637) as competitor (lane 4). Interestingly, the VLDL-induced factor was competed by both the 4G and 5G (Ϫ689/Ϫ665) probes (lane 6). This observation indicates that the VLDL-induced factor is bound within the region covering the Ϫ672 to Ϫ637 residues of the PAI-1 promoter adjacent to the binding site of the 5G allele-specific factor (Ϫ679/Ϫ673).
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Identification of the Binding Site of the VLDL-Inducible Transcription Factor
Footprinting studies using nuclear extract derived from VLDLinduced HUVECs were performed to map the specific binding site of the VLDL-inducible factor. Methylation interference (Fig 3A) and DNase I footprinting (Fig 3B) showed that the VLDL-induced factor is bound to the residues Ϫ672 to Ϫ657 of the PAI-1 promoter (Fig 3C) . To further study the involvement of this promoter element in the VLDL induction of the PAI-1 promoter, a 9-bp deletion (residues Ϫ662 to Ϫ670) of the VLDLRE was introduced into the 804-bp 4G-PAI-1 promoter construct (Fig 4A) . This deletion eliminated the VLDL induction of promoter activity (Fig 4B) . The wild-type 804-bp 4G-PAI-1 promoter construct was significantly induced by VLDL (2.0Ϯ0.6-fold induction, meanϮSD, nϭ4, PϽ.05 in a paired t test). In contrast, the mutated promoter showed no significant response to VLDL (1.3Ϯ0.5-fold induction, meanϮSD, nϭ4, Pϭ.31 in a paired t test).
VLDL-Inducible Factor Shows Competitive Binding With the Transcription Factors Binding to the 4G/5G Polymorphic Site
Since the VLDL-inducible factor was found to bind to the region adjacent to and partly overlapping the 4G/5G polymorphic site, competition between the 5G allele-specific transcriptional repressor protein 12 and the VLDL-induced factor could explain the 4G/5G allele-specific relations between VLDL triglyceride and PAI-1 activity levels in plasma. To resolve this issue, several binding sites were constructed for use in an EMSA (Fig 5) . Base pair substitutions were designed on the basis of the results of footprinting and methylation interference assays (Reference 12 and Fig 3) . Fig 6A shows an EMSA demonstrating the differential binding of the 4G/5G polymorphic site as previously described, 12 using the 4G or 5G alleles as probe. The EMSA shows that both alleles bound a common factor (factor A), while the 5G allele bound an additional factor (factor B). Additional complexes have earlier been shown to have nonspecific interactions. 12 Previous work has demonstrated that the common factor, factor A, acts as a transcriptional activator, whereas the 5G allele-specific factor, factor B, acts as a transcriptional repressor. 12 As demonstrated in Fig 6A, binding of factor B to the 5G allele results in a decreased binding of factor A compared with the 4G probe. To further study the interaction between factors B and A, two mutated EMSA probes were designed, containing mutations that impair the binding of factor A and factor B, respectively (Fig 5) . As shown in Fig 6B, competition of in an increased binding of factor A. Similarly, competition of factor A (Fig 6C) resulted in increased binding of factor B. Thus, the binding of the 5G allele-specific factor impaired the binding of the common transcriptional activator (factor A).
To study whether the 5G allele-specific repressor also influenced the binding of the VLDL-induced factor, EMSA probes were constructed that included the binding sites for both of these factors (Fig 5) . As demonstrated in Fig 7A, factor A and the VLDL-induced factor bound to the 4GϩVLDLRE construct, whereas the 5GϩVLDLRE construct also bound factor B. Densitometric scanning showed a 30% decrease in binding of the VLDL-induced factor to the 5GϩVLDLRE probe compared with the 4GϩVLDLRE. Furthermore, an interaction between factor B and the VLDL-induced factor was demonstrated by using a probe containing the B site and the VLDLRE but with a mutated binding site for factor A. As shown in Fig 7B, addition of VLDLRE as competitor decreased the binding of the VLDL-induced factor and increased the binding of factor B. Taken together, these studies show that the 5G allele-specific repressor can compete for binding to the PAI-1 promoter with both the common transcriptional activator (factor A) and the VLDL-induced factor.
Discussion
Increased PAI-1 expression in endothelial cells induced by VLDL may predispose to both arterial thrombosis and atherosclerosis by promoting persistence of fibrin on injured intimal surfaces and incorporation of fibrin into the artery wall. It is notable in this context that impaired fibrinolytic function secondary to elevated plasma PAI-1 activity has been shown to be of particular importance for myocardial infarction in men with hypertriglyceridemia. 17 However, the fairly strong positive relation between triglyceride and PAI-1 levels has been a consistent observation not only in young male postinfarction patients but also among healthy normolipidemic subjects, obese individuals, and patients with angina pectoris or NIDDM. 27 The evidence that PAI-1 plays a role in CHD now also extends beyond the rare cases of myocardial infarction before the age of 45. 3, 5, 28 The delineation in the present work of a molecular event in endothelial cells that could link hypertriglyceridemia to impaired fibrinolytic function not only reinforces the risk factor status of triglycerides but also may provide a molecular explanation of why lowering of plasma triglycerides reduce the plasma PAI-1 level and thus improve the fibrinolytic capacity, in line with the results obtained in a recent diet intervention study. 29 However, it needs to be emphasized that endothelial cells may not be the major source of plasma PAI-1 in hypertriglyceridemic individuals. It also remains to be established that VLDL actually increases endogenous PAI-1 gene transcription in the intact cell in the arterial endothelium.
The 4G/5G polymorphism in the PAI-1 promoter region was recently shown to be implicated in an allele-specific response to plasma triglycerides in patients with suspected CHD 14 or NIDDM. 15, 16 The present work disentangles the underlying molecular mechanisms. The VLDL-induced factor was found to bind to the region adjacent to and partly overlapping the binding site of the 5G allele. Competition between the 5G allele-specific transcriptional repressor protein 12 (factor B) and the VLDL-induced factor could explain the 4G/5G allele-specific relations between VLDL triglyceride and PAI-1 activity levels in plasma. In addition, competitive binding between the 5G allele-specific repressor and the common transcriptional activator could explain the differences in basal transcriptional activity.
Analysis of the VLDLRE showed that there is some homology with a peroxisome proliferator activator response element. The footprint included the sequence TCAGCC G TGTATC, which is similar to the peroxisome proliferator activator response element consensus sequence A/T C/G A C/A C T A/T T G/T N C C C/T. 30 The members of the PPAR family are ligand-dependent transcription factors that bind their cognate ligand with high affinity and specificity and then activate gene transcription through binding to a specific hormone response element in the promoter region of the target gene. The ligand activating PPAR is unknown. Interestingly, a variety of fatty acids can activate PPAR, 30 -34 and it has been proposed that fatty acids, or their acyl-CoA derivatives, are the natural ligands of PPAR and that the physiological role of PPAR is to regulate fatty acid homeostasis. 31 At this stage, one could speculate that fatty acids derived from VLDL triglycerides may cooperate to regulate the PAI-1 gene. In contrast to VLDL, native LDL has no effect on PAI-1 expression in endothelial cells. 35 This observation argues for a nutritional regulation of PAI-1 secretion from endothelial cells by fatty acids, as the major difference between VLDL and LDL is the high triglyceride content of the former. In fact, unsaturated fatty acids have been found to selectively increase PAI-1 mRNA levels in cultured HUVECs, 36 a finding that is in accordance with dietary studies showing that polyunsaturated fatty acids increase circulating PAI-1 levels. [37] [38] [39] Differences between populations in plasma PAI-1 levels and in the relationship of the 4G/5G polymorphism to plasma PAI-1 activity might thus be accounted for by differences in dietary habits.
In conclusion, the present work has contributed a molecular explanation to the link between VLDL and PAI-1 activity elevation in plasma and a direct mechanism by which hypertriglyceridemia may increase the risk of CHD and other atherothrombotic disorders.
